# Semantic-enhanced heterogeneous graph learning for identifying ncRNAs associated with drug resistance

**Authors:** Hang Wei, Yuran Xie, Wenxiang Zhang, Linyang Li, Shuai Wu, Lin Gao

PMC · DOI: 10.1093/bioinformatics/btag029 · Bioinformatics · 2026-01-14

## TL;DR

This paper introduces a new method to identify non-coding RNAs linked to drug resistance using an enhanced graph learning approach that improves accuracy and interpretability.

## Contribution

The novel iNcRD-HG framework integrates heterogeneous molecular interactions and semantic context for better ncRNA-drug resistance predictions.

## Key findings

- iNcRD-HG outperforms existing methods on benchmark datasets for ncRNA-drug resistance association prediction.
- The framework captures complex contextual dependencies through relation-type-aware message passing.
- It provides interpretable insights into synergistic pathways involved in drug resistance.

## Abstract

Identifying non-coding RNAs (ncRNAs) associated with drug resistance is critical for elucidating molecular mechanisms underlying drug response, facilitating drug screening, and discovering novel therapeutic targets. While several graph neural network-based methods have been proposed to infer ncRNA-drug resistance associations, they remain fundamentally constrained by semantic distortion induced by a sparse bipartite network and neglect of relational semantics among molecular entities, ultimately compromising both predictive reliability and biological interpretability.

In this study, we propose iNcRD-HG, a novel framework for identifying ncRNA-drug resistance associations. The framework addresses three critical aspects: constructing a context-enriched heterogeneous network that integrates six distinct molecular interaction types with bio-entity-specific attributes, developing a semantic-enhanced graph learning architecture that implements relation-type-aware message passing to capture complex contextual dependencies, and introducing an interpretability mechanism to reveal potential synergistic pathways underlying drug response. Experimental results demonstrate that iNcRD-HG achieves superior predictive performance across diverse benchmark datasets while deriving association features with strong discriminative capability. By identifying molecular synergistic contexts, iNcRD-HG provides mechanistically interpretable insights into ncRNA-mediated drug resistance.

Datasets and source codes are available at https://github.com/Biohang/iNcRD-HG.

## Full-text entities

- **Genes:** MCL1 (MCL1 apoptosis regulator, BCL2 family member) [NCBI Gene 4170] {aka BCL2L3, EAT, MCL1-ES, MCL1L, MCL1S, Mcl-1}, MALAT1 (metastasis associated lung adenocarcinoma transcript 1) [NCBI Gene 378938] {aka HCN, LINC00047, NCRNA00047, NEAT2, PRO2853, miPEP-52}, NORAD (non-coding RNA activated by DNA damage) [NCBI Gene 647979] {aka LINC00657}, NEAT1 (nuclear paraspeckle assembly transcript 1) [NCBI Gene 283131] {aka LINC00084, NCRNA00084, TP53LC15, TncRNA, VINC}, RRM2 (ribonucleotide reductase regulatory subunit M2) [NCBI Gene 6241] {aka C2orf48, R2, RR2, RR2M}, AFAP1-AS1 (AFAP1 antisense RNA 1) [NCBI Gene 84740] {aka AFAP1-AS, AFAP1AS, ATMLP}, MIR20A (microRNA 20a) [NCBI Gene 406982] {aka C13orf25, MIR20, MIRH1, MIRHG1, MIRN20, MIRN20A}, HMGA2 (high mobility group AT-hook 2) [NCBI Gene 8091] {aka BABL, HMGI-C, HMGIC, LIPO, SRS5, STQTL9}, NcRNA [NCBI Gene 54719], XIST (X inactive specific transcript) [NCBI Gene 7503] {aka DXS1089, DXS399E, LINC00001, NCRNA00001, SXI1, swd66}, MIR21 (microRNA 21) [NCBI Gene 406991] {aka MIRN21, hsa-mir-21, miR-21, miRNA21}, RAP1A (RAP1A, member of RAS oncogene family) [NCBI Gene 5906] {aka C21KG, G-22K, KREV-1, KREV1, RAP1, SMGP21}, SNHG16 (small nucleolar RNA host gene 16) [NCBI Gene 100507246] {aka ELNAT1, Nbla10727, Nbla12061, ncRAN}, ETS1 (ETS proto-oncogene 1, transcription factor) [NCBI Gene 2113] {aka ETS-1, EWSR2, c-ets-1, p54}, FCER1A (Fc epsilon receptor Ia) [NCBI Gene 2205] {aka FCE1A, FCERIA, FcERI}, ALB (albumin) [NCBI Gene 213] {aka FDAHT, HSA, PRO0883, PRO0903, PRO1341}, SNHG14 (small nucleolar RNA host gene 14) [NCBI Gene 104472715] {aka 115HG, IC-SNURF-SNRPN, IPW, LNCAT, NCRNA00002, NCRNA00214}, H19 (H19 imprinted maternally expressed transcript) [NCBI Gene 283120] {aka ASM, ASM1, BWS, D11S813E, GMRSP, LINC00008}, BCL2 (BCL2 apoptosis regulator) [NCBI Gene 596] {aka Bcl-2, PPP1R50}
- **Diseases:** metastasis (MESH:D009362), Tumor (MESH:D009369), HCC (MESH:D006528), NSCLC (MESH:D002289), multiple myeloma (MESH:D009101), neuroblastoma (MESH:D009447)
- **Chemicals:** Gem (MESH:D000093542), Fluorouracil (MESH:D005472), Gefitinib (MESH:D000077156), Temozolomide (MESH:D000077204), bortezomib (MESH:D000069286), CISPLATIN (MESH:D002945), Dox (MESH:D004317), Pac (MESH:D017239), Sorafenib (MESH:D000077157), taxane (MESH:C080625), GTP (MESH:D006160), Oxaliplatin (MESH:D000077150)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12866671/full.md

## Figures

7 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12866671/full.md

## References

63 references — full list in the complete paper: https://tomesphere.com/paper/PMC12866671/full.md

---
Source: https://tomesphere.com/paper/PMC12866671